Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination

Autores
Castro, Eliana Florencia; Acosta, Julián; Moriena, Lucía; Rios Medrano, Mayra; Cibello, Malena Tejerina; Codino, Eduardo; Taborda, Miguel Ángel; Álvarez, Diego E.; Cavatorta, Ana
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
SARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including neutralizing antibody response (NAT) against ancestral, Gamma, and Delta variants. The first seroprevalence study showed that among 122 individuals with one dose, 90.2% were seropositive versus 99.7% seropositivity among volunteers with the complete two-dose regimen. At 24 wpv, 98.7% of the volunteers remained seropositive, although antibody levels decreased. IgG levels and NAT were higher in individuals that had acquired COVID-19 previous to vaccination than in naive individuals at 2 and 24 wpv. Antibody levels dropped over time in both groups. In contrast, IgG levels and NAT increased after vaccine breakthrough infection. At 2 wpv, 35/40 naive individuals had detectable NAT against SARS-CoV-2 Gamma and 6/40 against Delta. In turn, 8/9 previously infected individuals developed a neutralizing response against SARS-CoV-2 Gamma and 4/9 against Delta variants. NAT against variants followed a trajectory similar to NAT against ancestral SARS-CoV-2, and breakthrough infection led to an increase in NAT and complete seroconversion against variants. In conclusion, Sputnik V-induced humoral response persisted at 6 months postvaccination, and hybrid immunity induced higher levels of anti-S/RBD antibodies and NAT in previously exposed individuals, boosted the response after vaccination, and conferred wider breadth of protection. IMPORTANCE Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people. Despite all the available information, there are fewer published studies on the response induced by Sputnik V vaccination compared to that of other vaccines. Although the global political context has paralyzed the verification by the WHO of the efficacy of this vaccine, our work aims to add new clear and necessary evidence to Sputnik V performance. Our results contribute to general knowledge of the humoral immune response developed by vaccines based on viral vector technology, highlighting the higher immune protection conferred by hybrid immunity and reinforcing the importance of completing vaccination schedules and booster doses to maintain adequate antibody levels.
Instituto de Virología
Fil: Castro, Eliana Florencia. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Castro, Eliana Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Castro, Eliana Florencia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Acosta, Julián. Instituto de Biología Molecular y Celular de Rosario; Argentina
Fil: Acosta, Julián. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Acosta, Julián. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Moriena, Lucía. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública (CTSP); Argentina
Fil: Rios Medrano, Mayra. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Rios Medrano, Mayra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin
Fil: Cibello, Malena Tejerina. Universidad Nacional de San Martín. Escuela de Bio y Nanotecnologías; Argentina
Fil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública; Argentina
Fil: Taborda, Miguel Ángel. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Álvarez, Diego E. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Álvarez, Diego E. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Cavatorta, Ana. Instituto de Biología Molecular y Celular de Rosario; Argentina
Fil: Cavatorta, Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología En Salud Pública; Argentina
Fuente
mSphere 8 (3) : e0066222 (June 2023)
Materia
Severe Acute Respiratory Syndrome Coronavirus 2
Humoral Immunity
Immune Response
Vaccination
Coronavirus del Síndrome Respiratorio Agudo Grave 2
Inmunidad Humoral
Respuesta Inmunológica
Vacunación
Argentina
Sputnik V
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/16603

id INTADig_2bb9b6e9ae986422269623907296f162
oai_identifier_str oai:localhost:20.500.12123/16603
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccinationCastro, Eliana FlorenciaAcosta, JuliánMoriena, LucíaRios Medrano, MayraCibello, Malena TejerinaCodino, EduardoTaborda, Miguel ÁngelÁlvarez, Diego E.Cavatorta, AnaSevere Acute Respiratory Syndrome Coronavirus 2Humoral ImmunityImmune ResponseVaccinationCoronavirus del Síndrome Respiratorio Agudo Grave 2Inmunidad HumoralRespuesta InmunológicaVacunaciónArgentinaSputnik VSARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including neutralizing antibody response (NAT) against ancestral, Gamma, and Delta variants. The first seroprevalence study showed that among 122 individuals with one dose, 90.2% were seropositive versus 99.7% seropositivity among volunteers with the complete two-dose regimen. At 24 wpv, 98.7% of the volunteers remained seropositive, although antibody levels decreased. IgG levels and NAT were higher in individuals that had acquired COVID-19 previous to vaccination than in naive individuals at 2 and 24 wpv. Antibody levels dropped over time in both groups. In contrast, IgG levels and NAT increased after vaccine breakthrough infection. At 2 wpv, 35/40 naive individuals had detectable NAT against SARS-CoV-2 Gamma and 6/40 against Delta. In turn, 8/9 previously infected individuals developed a neutralizing response against SARS-CoV-2 Gamma and 4/9 against Delta variants. NAT against variants followed a trajectory similar to NAT against ancestral SARS-CoV-2, and breakthrough infection led to an increase in NAT and complete seroconversion against variants. In conclusion, Sputnik V-induced humoral response persisted at 6 months postvaccination, and hybrid immunity induced higher levels of anti-S/RBD antibodies and NAT in previously exposed individuals, boosted the response after vaccination, and conferred wider breadth of protection. IMPORTANCE Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people. Despite all the available information, there are fewer published studies on the response induced by Sputnik V vaccination compared to that of other vaccines. Although the global political context has paralyzed the verification by the WHO of the efficacy of this vaccine, our work aims to add new clear and necessary evidence to Sputnik V performance. Our results contribute to general knowledge of the humoral immune response developed by vaccines based on viral vector technology, highlighting the higher immune protection conferred by hybrid immunity and reinforcing the importance of completing vaccination schedules and booster doses to maintain adequate antibody levels.Instituto de VirologíaFil: Castro, Eliana Florencia. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; ArgentinaFil: Castro, Eliana Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Castro, Eliana Florencia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Acosta, Julián. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Acosta, Julián. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Acosta, Julián. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; ArgentinaFil: Moriena, Lucía. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública (CTSP); ArgentinaFil: Rios Medrano, Mayra. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; ArgentinaFil: Rios Medrano, Mayra. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinFil: Cibello, Malena Tejerina. Universidad Nacional de San Martín. Escuela de Bio y Nanotecnologías; ArgentinaFil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; ArgentinaFil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública; ArgentinaFil: Taborda, Miguel Ángel. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; ArgentinaFil: Álvarez, Diego E. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; ArgentinaFil: Álvarez, Diego E. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Cavatorta, Ana. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Cavatorta, Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; ArgentinaFil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología En Salud Pública; ArgentinaAmerican Society for Microbiology2024-02-14T16:56:51Z2024-02-14T16:56:51Z2023-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/16603https://journals.asm.org/doi/10.1128/msphere.00662-222379-5042https://doi.org/10.1128/msphere.00662-22mSphere 8 (3) : e0066222 (June 2023)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-10-16T09:31:27Zoai:localhost:20.500.12123/16603instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-10-16 09:31:28.191INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination
title Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination
spellingShingle Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination
Castro, Eliana Florencia
Severe Acute Respiratory Syndrome Coronavirus 2
Humoral Immunity
Immune Response
Vaccination
Coronavirus del Síndrome Respiratorio Agudo Grave 2
Inmunidad Humoral
Respuesta Inmunológica
Vacunación
Argentina
Sputnik V
title_short Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination
title_full Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination
title_fullStr Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination
title_full_unstemmed Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination
title_sort Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination
dc.creator.none.fl_str_mv Castro, Eliana Florencia
Acosta, Julián
Moriena, Lucía
Rios Medrano, Mayra
Cibello, Malena Tejerina
Codino, Eduardo
Taborda, Miguel Ángel
Álvarez, Diego E.
Cavatorta, Ana
author Castro, Eliana Florencia
author_facet Castro, Eliana Florencia
Acosta, Julián
Moriena, Lucía
Rios Medrano, Mayra
Cibello, Malena Tejerina
Codino, Eduardo
Taborda, Miguel Ángel
Álvarez, Diego E.
Cavatorta, Ana
author_role author
author2 Acosta, Julián
Moriena, Lucía
Rios Medrano, Mayra
Cibello, Malena Tejerina
Codino, Eduardo
Taborda, Miguel Ángel
Álvarez, Diego E.
Cavatorta, Ana
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Severe Acute Respiratory Syndrome Coronavirus 2
Humoral Immunity
Immune Response
Vaccination
Coronavirus del Síndrome Respiratorio Agudo Grave 2
Inmunidad Humoral
Respuesta Inmunológica
Vacunación
Argentina
Sputnik V
topic Severe Acute Respiratory Syndrome Coronavirus 2
Humoral Immunity
Immune Response
Vaccination
Coronavirus del Síndrome Respiratorio Agudo Grave 2
Inmunidad Humoral
Respuesta Inmunológica
Vacunación
Argentina
Sputnik V
dc.description.none.fl_txt_mv SARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including neutralizing antibody response (NAT) against ancestral, Gamma, and Delta variants. The first seroprevalence study showed that among 122 individuals with one dose, 90.2% were seropositive versus 99.7% seropositivity among volunteers with the complete two-dose regimen. At 24 wpv, 98.7% of the volunteers remained seropositive, although antibody levels decreased. IgG levels and NAT were higher in individuals that had acquired COVID-19 previous to vaccination than in naive individuals at 2 and 24 wpv. Antibody levels dropped over time in both groups. In contrast, IgG levels and NAT increased after vaccine breakthrough infection. At 2 wpv, 35/40 naive individuals had detectable NAT against SARS-CoV-2 Gamma and 6/40 against Delta. In turn, 8/9 previously infected individuals developed a neutralizing response against SARS-CoV-2 Gamma and 4/9 against Delta variants. NAT against variants followed a trajectory similar to NAT against ancestral SARS-CoV-2, and breakthrough infection led to an increase in NAT and complete seroconversion against variants. In conclusion, Sputnik V-induced humoral response persisted at 6 months postvaccination, and hybrid immunity induced higher levels of anti-S/RBD antibodies and NAT in previously exposed individuals, boosted the response after vaccination, and conferred wider breadth of protection. IMPORTANCE Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people. Despite all the available information, there are fewer published studies on the response induced by Sputnik V vaccination compared to that of other vaccines. Although the global political context has paralyzed the verification by the WHO of the efficacy of this vaccine, our work aims to add new clear and necessary evidence to Sputnik V performance. Our results contribute to general knowledge of the humoral immune response developed by vaccines based on viral vector technology, highlighting the higher immune protection conferred by hybrid immunity and reinforcing the importance of completing vaccination schedules and booster doses to maintain adequate antibody levels.
Instituto de Virología
Fil: Castro, Eliana Florencia. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Castro, Eliana Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Castro, Eliana Florencia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Acosta, Julián. Instituto de Biología Molecular y Celular de Rosario; Argentina
Fil: Acosta, Julián. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Acosta, Julián. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Moriena, Lucía. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública (CTSP); Argentina
Fil: Rios Medrano, Mayra. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Rios Medrano, Mayra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin
Fil: Cibello, Malena Tejerina. Universidad Nacional de San Martín. Escuela de Bio y Nanotecnologías; Argentina
Fil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública; Argentina
Fil: Taborda, Miguel Ángel. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Álvarez, Diego E. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Álvarez, Diego E. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Cavatorta, Ana. Instituto de Biología Molecular y Celular de Rosario; Argentina
Fil: Cavatorta, Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología En Salud Pública; Argentina
description SARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including neutralizing antibody response (NAT) against ancestral, Gamma, and Delta variants. The first seroprevalence study showed that among 122 individuals with one dose, 90.2% were seropositive versus 99.7% seropositivity among volunteers with the complete two-dose regimen. At 24 wpv, 98.7% of the volunteers remained seropositive, although antibody levels decreased. IgG levels and NAT were higher in individuals that had acquired COVID-19 previous to vaccination than in naive individuals at 2 and 24 wpv. Antibody levels dropped over time in both groups. In contrast, IgG levels and NAT increased after vaccine breakthrough infection. At 2 wpv, 35/40 naive individuals had detectable NAT against SARS-CoV-2 Gamma and 6/40 against Delta. In turn, 8/9 previously infected individuals developed a neutralizing response against SARS-CoV-2 Gamma and 4/9 against Delta variants. NAT against variants followed a trajectory similar to NAT against ancestral SARS-CoV-2, and breakthrough infection led to an increase in NAT and complete seroconversion against variants. In conclusion, Sputnik V-induced humoral response persisted at 6 months postvaccination, and hybrid immunity induced higher levels of anti-S/RBD antibodies and NAT in previously exposed individuals, boosted the response after vaccination, and conferred wider breadth of protection. IMPORTANCE Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people. Despite all the available information, there are fewer published studies on the response induced by Sputnik V vaccination compared to that of other vaccines. Although the global political context has paralyzed the verification by the WHO of the efficacy of this vaccine, our work aims to add new clear and necessary evidence to Sputnik V performance. Our results contribute to general knowledge of the humoral immune response developed by vaccines based on viral vector technology, highlighting the higher immune protection conferred by hybrid immunity and reinforcing the importance of completing vaccination schedules and booster doses to maintain adequate antibody levels.
publishDate 2023
dc.date.none.fl_str_mv 2023-06
2024-02-14T16:56:51Z
2024-02-14T16:56:51Z
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/16603
https://journals.asm.org/doi/10.1128/msphere.00662-22
2379-5042
https://doi.org/10.1128/msphere.00662-22
url http://hdl.handle.net/20.500.12123/16603
https://journals.asm.org/doi/10.1128/msphere.00662-22
https://doi.org/10.1128/msphere.00662-22
identifier_str_mv 2379-5042
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv American Society for Microbiology
publisher.none.fl_str_mv American Society for Microbiology
dc.source.none.fl_str_mv mSphere 8 (3) : e0066222 (June 2023)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1846143567742894080
score 12.712165